A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer
- 1 January 1997
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 75 (2) , 287-294
- https://doi.org/10.1038/bjc.1997.47
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Chemotherapy-induced apoptosis in epithelial ovarian cancersPublished by Wolters Kluwer Health ,2000
- A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curveCancer Chemotherapy and Pharmacology, 1996
- Taxol-Induced Mitotic Block Triggers Rapid Onset of a p53-Independent Apoptotic PathwayMolecular Medicine, 1995
- Tumor markers in the management of patients with ovarian cancerCancer Treatment Reviews, 1995
- Extensive and saturable accumulation of paclitaxel by the human plateletCancer Chemotherapy and Pharmacology, 1995
- Chemotherapy in Advanced Ovarian Carcinoma: Current Standards of Care Based on Randomized TrialsGynecologic Oncology, 1994
- Paclitaxel (Taxol) therapy in ovarian carcinoma.1993
- Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.Journal of Clinical Oncology, 1992
- A Comparison of the Toxicity and Efficacy of Cisplatin and Carboplatin in Advanced Ovarian CancerActa Oncologica, 1989
- A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma.Journal of Clinical Oncology, 1986